Health & Biotech
Check out the latest COVID-19 and Coronavirus news, insights and unique analysis brought to you by Stockhead’s team of business journalists and industry experts.
Mining
Monsters of Rock: Some of these booming lithium exploration stocks are creeping up on us
Mining
Monsters of Rock: Hoping for an end to China’s lockdowns, metal heads? Don’t count on it
Experts
Dr Boreham’s Crucible: Three out of four quarters says trust your about gut about Genetic Signatures
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
Interim results show MGC Pharma’s CimetrA dose finding study on right track
News
Once shunned, Viva Leisure and these ASX stocks are making a comeback post-Covid
Health & Biotech
CLARITY 2.0 Covid-19 study involving Dimerix’s lead drug concludes patient recruitment
Health & Biotech
‘Revenues and profitability will steadily increase’: Equity firm says undervalued EZZ set up for future growth
News
Closing Bell: Tech takes control as Asia Pacific markets rise en masse
Health & Biotech
MGC Pharma’s shares spike more than 20pc on positive trial of ArtemiC Support into Long Covid
Health & Biotech
Data analysis of COVID-19 study using Dimerix’ treatment DMX-200 is officially under way
Health & Biotech
Medlab wants to get right up COVID’s nose, as nasal vaccine program gathers steam
Health & Biotech
Dimerix hits more key milestones in Q3, as major global trials across its core product suite continue to advance
Health & Biotech
Dr Boreham’s Crucible: Can RATs in the ranks lead Atomo to our home-testing utopia?
News
CAN WE FIX IT? The ASX construction stocks fighting bankruptcy, materials and labour shortages to service massive forecast growth
Health & Biotech
SKN delivers hundreds of thousands of litres of its Covid-killing, plant-based, TGA-backed ‘SuprCuvr’ as latest deal pays off
Health & Biotech
Punching the lights out: Best half year ever for MGC Pharma as it triples revenue, aims to convert clinical trials to sales
Health & Biotech
Dimerix announces changes to investigator-led remap-cap Covid-19 study
Health & Biotech
Dimerix’s trading update confirms 2022 an exciting year as clinical development pathway advances
Health & Biotech
PharmAust gets massive expertise boost as final preparations begin for COVID-19 clinical trial
Health & Biotech
PharmAust on schedule for upcoming human trials for MND & COVID
Health & Biotech
Dimerix hits key milestone in Europe with first regulatory approval for its Phase 3 FSGS study, shares jump
Health & Biotech
PharmAust pushes forward with lead drug monepantel, four clinical trials to rollout
Health & Biotech
With a big year ahead, excitement is building for Dimerix’s global COVID-19 studies where results are due this quarter
Health & Biotech
Skin Elements secures major distribution deal for COVID-19 disinfectant spray
News
Weekly Small Cap and IPO Wrap: Like Mentos to Coke
Health & Biotech
Dimerix on a tear as patients line up for Phase 3 testing of COVID-19 treatment
Health & Biotech
This fundie reckons MGC Pharma can soar well over 3x current share price
Experts
Twenty-One of the Best: Tim Boreham’s Hot Stocks for 2022
Health & Biotech
Dimerix wins more government funding to commercialise its COVID-19 therapy
Health & Biotech
MGC Pharma pilots COVID-19 supplement, expects to benefit millions
Health & Biotech
This ASX biotech is one of the few running a Phase 3 clinical trial against COVID-19, and it’s firmly on track to proceed
Health & Biotech
IDT falls 40pc after Morrison government rejection; what now for the company’s COVID vaccine manufacturing ambitions?
Health & Biotech
MGC Pharma secures $10m capital raise from US and UK investors to advance development for its lead drug candidate, CimetrA
Health & Biotech
MGC Pharma set for best half-yearly results after delivering ArtemiC order in Europe
Health & Biotech
Aegros pockets license from TGA and flags capital raising, as it aims to disrupt the $19bn plasma market
Health & Biotech
MGC Pharma opens new production facility in Malta, now set to ramp up sales of CimetrA
Health & Biotech
With record growth in 2021, MGC Pharma’s Q1 trading update confirmed it’s laid the foundation for a global expansion
News
Reporting Season Round Up: The good times roll on for COVID beneficiary stocks
Health & Biotech
Dimerix builds on strategic Sydney Uni partnership to expand global COVID-19 treatment study into Australia
Tech
How the MultiSec Shield platform can provide a global solution to fake COVID-19 vax records, with YPB chairman John Houston
Health & Biotech
MGC Pharma lands milestone US$3 million CimetrA purchase order
Health & Biotech
Biotech Dimerix now has a ‘pathway to market’ with its latest oversubscribed capital raise
Health & Biotech
Australian Clinical Labs flags revenue boost, amid a surge in COVID-19 testing demand
Health & Biotech
Dimerix shares soar almost 8% on Indian COVID study update
Health & Biotech
Here’s why this fundie expects MGC Pharma’s stock price to more than double
Health & Biotech
MGC Pharma makes inroads in the fight against COVID-19, getting a regulatory nod in Germany and a successful trial in India
Load More
